Clinical Trials at Memorial Sloan Kettering Cancer Center

As of July 2026, 472 paid clinical trials are recruiting at Memorial Sloan Kettering Cancer Center, located at 1275 YORK AVE, MEMORIAL 7, NEW YORK, NY 10065-6007, phone (212) 639-2000 in New York, New York. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 16, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

472 clinical trials at Memorial Sloan Kettering Cancer Center

·Clear filters·↓ Download CSV

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

for Metastatic Uveal Melanoma

Drug: Nivolumab

29 locations incl. Scottsdale

Sponsor: Replimune, Inc.

Sex: All·Age: All ages

Code: NCT06581406·Phase 2, Phase 3·Recruiting

Apply to this trial

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

for Cancer Harboring BRAF Alterations

30 locations incl. Beverly Hills

Sponsor: Fore Biotherapeutics

Sex: All·Age: 10+

Code: NCT05503797·Phase 2·Recruiting

Apply to this trial

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

for Prostate Cancer

32 locations incl. Birmingham

Sponsor: Janux Therapeutics

Sex: Male·Age: 18 - 100

Code: NCT05519449·Phase 1·Recruiting

Apply to this trial

Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

41 locations incl. Birmingham

Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Sex: All·Age: 18+

Code: NCT06297226·Phase 2·Recruiting

Apply to this trial

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for AML

38 locations incl. Gilbert

Sponsor: Kura Oncology, Inc.

Sex: All·Age: 18+

Code: NCT06001788·Phase 1·Recruiting

Apply to this trial

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

for Neoplasms

30 locations incl. Birmingham

Sponsor: Eli Lilly and Company

Sex: All·Age: 1 - 39

Code: NCT05999994·Phase 2·Recruiting

Apply to this trial

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

for Advanced Melanoma

Drug: Tebentafusp

25 locations incl. Phoenix

Sponsor: Immunocore Ltd

Sex: All·Age: 18+

Code: NCT05549297·Phase 3·Recruiting

Apply to this trial

Prospective Study to Assess a Diagnostic Aid for Cancer

for Cancer

39 locations incl. Coronado

Sponsor: Harbinger Health

Sex: All·Age: 45+

Code: NCT07046260·Recruiting

Apply to this trial

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

for Non-small Cell Lung Cancer

38 locations incl. Duarte

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT04302025·Phase 2·Recruiting

Apply to this trial

A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

for Myelofibrosis

32 locations incl. Birmingham

Sponsor: Sumitomo Pharma America, Inc.

Sex: All·Age: 18+

Code: NCT04176198·Phase 1, Phase 2·Recruiting

Apply to this trial

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

for Relapsed Hematologic Malignancy

Drug: Emavusertib

27 locations incl. Phoenix

Sponsor: Curis, Inc.

Sex: All·Age: 18+

Code: NCT03328078·Phase 1, Phase 2·Recruiting

Apply to this trial

(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

for Advanced Gastrointestinal Stromal Tumors

36 locations incl. Birmingham

Sponsor: Cogent Biosciences, Inc.

Sex: All·Age: 18+

Code: NCT05208047·Phase 3·Recruiting

Apply to this trial

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

for Adenocarcinoma, Pancreatic Ductal

Drug: Atezolizumab

32 locations incl. Los Angeles

Sponsor: Genentech, Inc.

Sex: All·Age: 18+

Code: NCT05968326·Phase 2·Recruiting

Apply to this trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

for HER2-positive Breast Cancer

27 locations incl. Long Beach

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT07102381·Phase 2·Recruiting

Apply to this trial

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

for Breast Cancer

17 locations incl. Prescott

Sponsor: Jazz Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06695845·Phase 2·Recruiting

Apply to this trial

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

for Endometrial Cancer

18 locations incl. La Jolla

Sponsor: Faeth Therapeutics

Sex: Female·Age: 18+

Code: NCT06463028·Phase 2·Recruiting

Apply to this trial

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

for Non-small Cell Lung Cancer

22 locations incl. Glendale

Sponsor: Nuvalent Inc.

Sex: All·Age: 18+

Code: NCT06765109·Phase 3·Recruiting

Apply to this trial

A Study of ASP3082 in Adults With Advanced Solid Tumors

for Solid Tumor

25 locations incl. Duarte

Sponsor: Astellas Pharma Inc

Sex: All·Age: 18+

Code: NCT05382559·Phase 1·Recruiting

Apply to this trial

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

for Relapsed/Refractory Primary Central Nervous System Lymphoma

Drug: Rituximab

20 locations incl. Phoenix

Sponsor: Ono Pharmaceutical Co., Ltd.

Sex: All·Age: 18+

Code: NCT07104032·Phase 3·Recruiting

Apply to this trial

ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer

for Breast Cancer, Metastatic

21 locations incl. Tucson

Sponsor: ALX Oncology Inc.

Sex: All·Age: 18+

Code: NCT07007559·Phase 2·Recruiting

Apply to this trial

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

for Gastric Adenocarcinoma

17 locations incl. Phoenix

Sponsor: SystImmune Inc.

Sex: All·Age: 18+

Code: NCT07021066·Phase 1·Recruiting

Apply to this trial

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

for Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

21 locations incl. Santa Barbara

Sponsor: Amgen

Sex: All·Age: 18 - 100

Code: NCT05920356·Phase 3·Recruiting

Apply to this trial

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

for Solid Tumors

Drug: INCB161734

16 locations incl. Phoenix

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT06179160·Phase 1·Recruiting

Apply to this trial

A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors

for Ovarian Cancer

14 locations incl. Denver

Sponsor: OnCusp Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06234423·Phase 1·Recruiting

Apply to this trial

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

for Metastatic Solid Tumor

17 locations incl. Santa Monica

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06561685·Phase 1·Recruiting

Apply to this trial

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

for Pancreatic Cancer

Drug: daraxonrasib

11 locations incl. Tampa

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT07491445·Phase 3·Recruiting

Apply to this trial

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

for Metastatic Solid Tumor

Drug: LY4052031

18 locations incl. Duarte

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06465069·Phase 1·Recruiting

Apply to this trial

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

for Non-small Cell Lung Cancer

22 locations incl. Birmingham

Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

Sex: All·Age: 18+

Code: NCT06343402·Phase 1·Recruiting

Apply to this trial

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

for Extensive Stage Small Cell Lung Cancer

Drug: Tarlatamab

13 locations incl. Gilbert

Sponsor: Amgen

Sex: All·Age: 18 - 90

Code: NCT07037758·Phase 1·Recruiting

Apply to this trial

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

for Non-small Cell Lung Cancer (NSCLC)

12 locations incl. Los Angeles

Sponsor: Nuvation Bio Inc.

Sex: All·Age: 18+

Code: NCT07154706·Phase 3·Recruiting

Apply to this trial

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

for Pancreatic Ductal Adenocarcinoma (PDAC)

15 locations incl. Cerritos

Sponsor: SOFIE

Sex: All·Age: 18+

Code: NCT07217717·Phase 3·Recruiting

Apply to this trial

A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma

for Renal Cell Carcinoma

20 locations incl. Tucson

Sponsor: HiberCell, Inc.

Sex: All·Age: 18+

Code: NCT06234605·Phase 1·Recruiting

Apply to this trial

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

for Non-Small Cell Lung Cancer (NSCLC)

Drug: daraxonrasib

21 locations incl. Duarte

Sponsor: Revolution Medicines, Inc.

Sex: All·Age: 18+

Code: NCT06128551·Phase 1, Phase 2·Recruiting

Apply to this trial

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.

for Esophageal Cancer

15 locations incl. Cerritos

Sponsor: SOFIE

Sex: All·Age: 18+

Code: NCT07217704·Phase 3·Recruiting

Apply to this trial

A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies

for NSCLC

Drug: EP0031

21 locations incl. Los Angeles

Sponsor: Ellipses Pharma

Sex: All·Age: 18+

Code: NCT05443126·Phase 1, Phase 2·Recruiting

Apply to this trial

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

for Advanced Solid Tumor

Drug: Tulmimetostat

22 locations incl. Tampa

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT04104776·Phase 1, Phase 2·Recruiting

Apply to this trial

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

for PDAC

18 locations incl. Scottsdale

Sponsor: Tango Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06922591·Phase 1, Phase 2·Recruiting

Apply to this trial

Study of INCB123667 in Subjects With Advanced Solid Tumors

for Solid Tumors

Drug: INCB123667

19 locations incl. Duarte

Sponsor: Incyte Corporation

Sex: All·Age: 18+

Code: NCT05238922·Phase 1·Recruiting

Apply to this trial

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

for Acute Myeloid Leukemia

Drug: Revumenib

22 locations incl. Duarte

Sponsor: Syndax Pharmaceuticals

Sex: All·Age: 30 Days+

Code: NCT04065399·Phase 1, Phase 2·Recruiting

Apply to this trial

Pivotal Study of Voro Urologic Scaffold

for Radical Prostatectomy

19 locations incl. Phoenix

Sponsor: Levee Medical, Inc.

Sex: Male·Age: 45+

Code: NCT06873581·Phase 3·Recruiting

Apply to this trial